CN103923934A - 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 - Google Patents
一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 Download PDFInfo
- Publication number
- CN103923934A CN103923934A CN201410107482.0A CN201410107482A CN103923934A CN 103923934 A CN103923934 A CN 103923934A CN 201410107482 A CN201410107482 A CN 201410107482A CN 103923934 A CN103923934 A CN 103923934A
- Authority
- CN
- China
- Prior art keywords
- protein
- cpl
- gene
- preparation
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title abstract description 13
- 230000033228 biological regulation Effects 0.000 title abstract description 4
- 230000003053 immunization Effects 0.000 title abstract 3
- 238000002649 immunization Methods 0.000 title abstract 3
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 235000018102 proteins Nutrition 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 abstract description 5
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229960003444 immunosuppressant agent Drugs 0.000 abstract description 2
- 230000001861 immunosuppressant effect Effects 0.000 abstract description 2
- 206010062016 Immunosuppression Diseases 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000003828 downregulation Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003292 glue Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GORKKVHIBWAQHM-GCJQMDKQSA-N Ala-Asn-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GORKKVHIBWAQHM-GCJQMDKQSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- VYSRNGOMGHOJCK-GUBZILKMSA-N Arg-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N VYSRNGOMGHOJCK-GUBZILKMSA-N 0.000 description 1
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 1
- KSHJMDSNSKDJPU-QTKMDUPCSA-N Arg-Thr-His Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KSHJMDSNSKDJPU-QTKMDUPCSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 1
- LSJQOMAZIKQMTJ-SRVKXCTJSA-N Asn-Phe-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LSJQOMAZIKQMTJ-SRVKXCTJSA-N 0.000 description 1
- YHXNKGKUDJCAHB-PBCZWWQYSA-N Asn-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O YHXNKGKUDJCAHB-PBCZWWQYSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- DRCOAZZDQRCGGP-GHCJXIJMSA-N Asp-Ser-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DRCOAZZDQRCGGP-GHCJXIJMSA-N 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- BVFQOPGFOQVZTE-ACZMJKKPSA-N Cys-Gln-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O BVFQOPGFOQVZTE-ACZMJKKPSA-N 0.000 description 1
- AOZBJZBKFHOYHL-AVGNSLFASA-N Cys-Glu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O AOZBJZBKFHOYHL-AVGNSLFASA-N 0.000 description 1
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 1
- KJJASVYBTKRYSN-FXQIFTODSA-N Cys-Pro-Asp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CC(=O)O)C(=O)O KJJASVYBTKRYSN-FXQIFTODSA-N 0.000 description 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- VVWWRZZMPSPVQU-KBIXCLLPSA-N Gln-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N VVWWRZZMPSPVQU-KBIXCLLPSA-N 0.000 description 1
- JKGHMESJHRTHIC-SIUGBPQLSA-N Gln-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JKGHMESJHRTHIC-SIUGBPQLSA-N 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- LGWNISYVKDNJRP-FXQIFTODSA-N Gln-Ser-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGWNISYVKDNJRP-FXQIFTODSA-N 0.000 description 1
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 1
- YKLNMGJYMNPBCP-ACZMJKKPSA-N Glu-Asn-Asp Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YKLNMGJYMNPBCP-ACZMJKKPSA-N 0.000 description 1
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 1
- DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 1
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 1
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 1
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
- JLJLBWDKDRYOPA-RYUDHWBXSA-N Gly-Gln-Tyr Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JLJLBWDKDRYOPA-RYUDHWBXSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 1
- MKIAPEZXQDILRR-YUMQZZPRSA-N Gly-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN MKIAPEZXQDILRR-YUMQZZPRSA-N 0.000 description 1
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 description 1
- YPLYIXGKCRQZGW-SRVKXCTJSA-N His-Arg-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YPLYIXGKCRQZGW-SRVKXCTJSA-N 0.000 description 1
- FYTCLUIYTYFGPT-YUMQZZPRSA-N His-Gly-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FYTCLUIYTYFGPT-YUMQZZPRSA-N 0.000 description 1
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 1
- DYKZGTLPSNOFHU-DEQVHRJGSA-N His-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N DYKZGTLPSNOFHU-DEQVHRJGSA-N 0.000 description 1
- RNAYRCNHRYEBTH-IHRRRGAJSA-N His-Met-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O RNAYRCNHRYEBTH-IHRRRGAJSA-N 0.000 description 1
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 1
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 1
- SJLVSMMIFYTSGY-GRLWGSQLSA-N Ile-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SJLVSMMIFYTSGY-GRLWGSQLSA-N 0.000 description 1
- KBAPKNDWAGVGTH-IGISWZIWSA-N Ile-Ile-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KBAPKNDWAGVGTH-IGISWZIWSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- WMTOVWLLDGQGCV-GUBZILKMSA-N Leu-Glu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WMTOVWLLDGQGCV-GUBZILKMSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 1
- ARNIBBOXIAWUOP-MGHWNKPDSA-N Leu-Tyr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ARNIBBOXIAWUOP-MGHWNKPDSA-N 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- OGAZPKJHHZPYFK-GARJFASQSA-N Met-Glu-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGAZPKJHHZPYFK-GARJFASQSA-N 0.000 description 1
- LRALLISKBZNSKN-BQBZGAKWSA-N Met-Gly-Ser Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LRALLISKBZNSKN-BQBZGAKWSA-N 0.000 description 1
- JOYFULUKJRJCSX-IUCAKERBSA-N Met-Met-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O JOYFULUKJRJCSX-IUCAKERBSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 1
- NJONQBYLTANINY-IHPCNDPISA-N Phe-Trp-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(O)=O NJONQBYLTANINY-IHPCNDPISA-N 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- QDDJNKWPTJHROJ-UFYCRDLUSA-N Pro-Tyr-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 QDDJNKWPTJHROJ-UFYCRDLUSA-N 0.000 description 1
- SWIQQMYVHIXPEK-FXQIFTODSA-N Ser-Cys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O SWIQQMYVHIXPEK-FXQIFTODSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
- CAOYHZOWXFFAIR-CIUDSAMLSA-N Ser-His-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CAOYHZOWXFFAIR-CIUDSAMLSA-N 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- ANOQEBQWIAYIMV-AEJSXWLSSA-N Ser-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N ANOQEBQWIAYIMV-AEJSXWLSSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- YBXMGKCLOPDEKA-NUMRIWBASA-N Thr-Asp-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YBXMGKCLOPDEKA-NUMRIWBASA-N 0.000 description 1
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 1
- YUPVPKZBKCLFLT-QTKMDUPCSA-N Thr-His-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N)O YUPVPKZBKCLFLT-QTKMDUPCSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- KOVPHHXMHLFWPL-BPUTZDHNSA-N Trp-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CC(=O)N)C(=O)O KOVPHHXMHLFWPL-BPUTZDHNSA-N 0.000 description 1
- GFZQWWDXJVGEMW-ULQDDVLXSA-N Tyr-Arg-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GFZQWWDXJVGEMW-ULQDDVLXSA-N 0.000 description 1
- DMWNPLOERDAHSY-MEYUZBJRSA-N Tyr-Leu-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DMWNPLOERDAHSY-MEYUZBJRSA-N 0.000 description 1
- VXFXIBCCVLJCJT-JYJNAYRXSA-N Tyr-Pro-Pro Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O VXFXIBCCVLJCJT-JYJNAYRXSA-N 0.000 description 1
- CWSIBTLMMQLPPZ-FXQIFTODSA-N Val-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N CWSIBTLMMQLPPZ-FXQIFTODSA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于分子免疫学技术领域，具体为一种具有免疫负调控作用的基因工程蛋白CPL及其制备方法与应用。本发明首先提供一种CPL基因，其核苷酸序列如SEQIDNO：1所示。本发明还提供上述基因所编码的融合蛋白CPL，其氨基酸序列SEQIDNO：2所示。本发明还提供前述融合蛋白CPL的制备方法和免疫调控效果（免疫抑制）以及用途。本发明提供的基因工程蛋白可以有效阻止T细胞活化，具有显著免疫抑制作用，可用于制备免疫抑制剂。本发明为研发防治自身免疫疾病，抗移植排斥及超敏反应的药物开辟广阔前景。
Description
技术领域
本发明属于分子免疫学技术领域，具体涉及一种具有免疫负调控作用的基因工程蛋白CPL及其制备方法与应用。
背景技术
免疫反应过度激活引起的疾病在临床上非常普遍，包括类风湿性关节炎，红斑狼疮等自身免疫病和器官移植急性排斥等。对机体非正常的免疫应答的调控研究一直以来都是免疫学主要任务之一。免疫应答过激的主要机制在于体内病理性淋巴细胞的激活，使T细胞攻击自体组织或移植组织，同时产生抗体，造成移植物排斥或炎症反应。早期临床上主要应用糖皮质激素和钙调磷酸酶抑制剂等副作用较大的免疫抑制药物进行治疗
传统的免疫抑制药物如糖皮质激素，烷化剂和抗代谢药物，如临床常用的FK506和Ciclosporin A等虽然有效，但特异性仍不够理想。开发更安全，特异性更好的免疫抑制剂一直是免疫学的重要研究方向。新的药物要求能在抑制对异体器官排斥的同时，并不降低病原菌和肿瘤的正常免疫应答。由于在一个完整免疫应答的过程中，T细胞的激活需经历: T细胞表面的T细胞受体与抗原递呈细胞表面的MHC多肽复合物结合的第一信号；抗原递呈细胞表面的B7与T细胞表面的CD28分子结合的共刺激信号；除此之外，T细胞活化增殖分化还需要IL－2等细胞因子的帮助，称为第三信号。因此新一代的免疫抑制剂可特异性作用于淋巴细胞活化的这几个信号传导通路中，阻断T细胞活化信号，诱导免疫无反应性或无能。
本发明所涉及蛋白，具有两个功能结构域，能在有效抑制共刺激信号的同时，传导免疫负调控信号，特异性的高效抑制T细胞活化。
发明内容
本发明目的在于提供一种具有高效免疫负调控作用的基因工程蛋白CPL及其制备方法与应用。
本发明提供的具有高效免疫负调控作用的新型基因工程蛋白，其成分具有两个功能结构域，分别为结构域P和结构域C，并在两个功能结构域之间引入了柔性铰链区，以使两个结构域能分别正确折叠，记为CPL。该基因工程蛋白也称为免疫负调控分子，
本发明首先提供一种基因，该基因的核苷酸序列如SEQ ID NO: 1所示，命名为CPL基因。
本发明还提供一种重组载体，它包含前述CPL基因。其中，所述的重组载体是重组pet28a质粒。
本发明还提供一种基因工程重组的可表达CPL蛋白质的原核和真核细胞（菌株及细胞株），即重组菌,它包含所述的重组基因及其重组载体。所述重组菌可以为大肠埃希氏杆菌。
本发明还提供前述基因编码的蛋白质，命名为CPL分子（即融合蛋白或基因工程蛋白）。其中，所述蛋白质的氨基酸序列如SEQ ID NO: 2所示。
本发明还提供前述融合蛋白的制备方法。
I.取所述的重组菌，以1:10~1:100的接种量转接于LB培养基中；200rpm/min培养至OD600为0.2～1.0之间；
II．加入终浓度为0.1~1.0mmol的IPTG为诱导剂，温度为30~40℃，诱导培养2~24h；
III．收集菌体，破壁，分离纯化，得到目的蛋白。
上述方法中，优选参数为：所述的重组菌以1:25-1：50的接种量转接于LB培养基中，培养至OD600为0.4～0.6之间；诱导剂终浓度为：0.2~0.5mmol，诱导温度30~40℃，诱导时间2~6h。
研究表明，上述融合蛋白CPL分子，具有高效免疫负调控作用，可以用于制备一种高效免疫抑制剂。具体地说，该融合蛋白可抑制CD28与 B7分子结合，进而抑制T细胞活化。另外，该融合蛋白通过与CD279结合产生免疫负调控信号，进而起到免疫抑制作用。
本发明还提供一种新型免疫抑制剂，其有效成分为前述蛋白质。
附图说明
图1 结构域P和结构域C以及新型基因工程蛋白全长编码基因的PCR。
图2新型基因工程蛋白原核表达载体阳性转化子的PCR鉴定。
图3 SDS-PAGE分析新型基因工程蛋白Ni-NTA亲和柱纯化产物。
图4 Western Blot鉴定新型基因工程融合蛋白。
图5 混合淋巴反应结果。
图6 ConA转化实验结果。
具体实施方式
合成如下引物用于克隆：
1）结构域P第一外显子克隆引物
DomainP-U1： 5’-TCTCTCGAGAAAAGATTATTCACAGTGACAGT-3’ （SEQ ID NO: 3）
XhoI
DomainP -D1: 5’-TAAGGTCTCACTTTGACTTTCAGAGT-3’ （SEQ ID NO: 4）
Eco31I
2）结构域P第二外显子+第三外显子克隆引物
DomainP-U2: 5’-TATGGTCTCAAAAGCTTCCTACAGGAAAATAAA-3’ （SEQ ID NO: 5）
Ecol31I
DomainP-D2: 5’-ATAGCGGCCGCTTAATGATGATGATGATGATGAGTTGGATGGGT
NotI
CCTGGGTTCCATCTGACTTTGAAGGTCAATGC-3’ （SEQ ID NO: 6）
3）全长蛋白克隆引物
Comp-U1 ：5’-AGCCATATGTTATTCACAGTGACAG-3’ （SEQ ID NO: 7）
NdeI
Comp-D1：5’-ATAGGATCCACCGCCAGTTGGATGGGTCCTGGGTT-3’（SEQ ID NO: 8）
BamHI
Comp-U2：5’-ATAGGATCCATGCATGTTGCTCAACC-3’ （SEQ ID NO: 9）
BamHI
Comp-D2：5’-ATAGCGGCCGCTTAATCAGAATCTGGAC-3’ （SEQ ID NO: 10）
NotI
1．目的片段的获得
1.1 结构域P外显子的PCR
第一外显子PCR，按如下体系加样
PCR条件：
95℃ 5min → 94℃ 10s → 55℃ 10s → 72℃ 30s,30循环→72℃ 5min。
第二外显子+第三外显子29bp PCR，按如下体系加样
PCR条件95℃ 5min → 94℃ 10s → 55℃ 10s → 72℃ 60s， 30循环→ 72℃ 5min，PCR产物电泳后，进行胶回收，胶回收步骤：
1) 取5μl PCR产物走1%的琼脂糖电泳，鉴定条带大小无误；
2) 将所有PCR产物上样走1%的琼脂糖电泳；
3) 在紫外灯下将扩增条带切下，放入1.5ml离心管，并称重；
4) 按每100 mg琼脂糖加入100μl DE-A液的比例加入 DE-A液，置70 ℃水浴使琼脂糖完全溶化；
5) 按每100μl DE-A加入300μl DE-B溶液的比例加入DE-B ；
6) 混匀后将液体移入吸附柱，12000rpm离心30s.倒掉收集管中的液体，再将吸附柱放入同一个收集管中；
7) 在吸附柱中加入500μl W1液，12000rpm离心30s.倒掉收集管中的液体，将吸附柱放入同一个收集管；
8) 在吸附柱中加入700μl W2液，12000rpm离心30s.倒掉收集管中的液体，将吸附柱放入同一个收集管；
9) 离心2钟后，将吸附柱放入一个干净的1.5ml的离心管中，在吸附膜中央加入40μl温育过的MilliQ H2O，静置2分钟后，12000rpm离心一分钟。
结构域P外显子的拼接
在第一外显子下游引物和第二外显子上游引物中引入ⅡS型限制性内切酶位点Ecol31I，用同序异尾酶方法实现外显子之间的拼接。
载体及PCR片段的酶切
第一外显子的的酶切：按如下体系加样，37 ℃水浴反应3h
第二+三外显子的酶切：按如下体系加样，37 ℃水浴反应5h
载体双酶切：按如下体系加样，37 ℃水浴反应5h
酶切产物胶回收步骤同前述。
酶切产物连接连接
连接条件：16℃连接过夜。
转化DH5a和转化子鉴定：
试剂配制
1) TSB (5ml): LB3.9ml, 10% PEG3350 0.5ml, 5%DMSO 25μl, 10mM MgCl2 0.0102g, 10mM MgSO4 0.0123g, 10% 甘油
2) 5×KCM (5ml): 0.5M KCl 0.186g, 0.15M CaCl2 0.083g, 0.25M MgCl2 0.25g。
感受态细胞的制备
1) 接DH5a单菌落到5mL LB培养液，37℃振摇培养过夜；
2) 取200μl过夜培养物,转接到20mL LB中,于37℃振摇培养约2小时左右，至菌液的OD值达到约0.4；
3) 将菌液4℃，6000rpm离心5min，弃上清；
4) 加入1/10体积的预冷TSB悬浮沉淀,混匀后冰浴10min；
5) 以50μl/管分装于1.5ml离心管中，-80℃保存。
连接产物转化DH5a
1) 取连接产物5μl，MilliQ H2O 35μl，5×KCM 10μl混匀置于冰上；
2) 取出-80℃保存的DH5a感受态细胞冰浴溶化后加入步骤1中的混合物；
3) 冰浴20min，室温放置10min；
4) 加入500μl预热的LB培养基，150rpm振荡45min；
5) 离心吸弃部分培养基后取50μl左右涂布含Kna的LB平板；
6) 平板37 ℃倒置培养过夜。
法鉴定重组子
1) 挑取转化板的菌落，接入0.5ml LB，37 ℃ 220rpm培养5h ；
2) 用上下游引物和Taq酶以2）中所述的离心上清为模板进行PCR扩增检测，体系如下：
20μlPCR鉴定反应体系：
阳性对照加入PCR模版pPIC9K-Domain C 0.5μl，阴性对照不加入任何模版。
3) PCR扩增反应条件：
4) 取10μl PCR产物，1%的琼脂糖电泳检测。
全长蛋白表达载体的构建
利用pPICZa-Domain C和pPICZa-Domain P质粒为模版克隆构建全长CPL蛋白pet28a表达质粒。为了使两个结构域能够正确折叠，在两个分子之间引入柔性铰链区结构，同时由于铰链区编码基因内存在一个BamHI位点，便于两段基因片段的拼接。
DomainP片段的PCR和酶切纯化
DomainP片段PCR，按如下体系加样
PCR条件：
酶切体系如下：
37℃水浴，酶切5h。
DomainC片段的PCR和酶切纯化
DomainC片段PCR，按如下体系加样，PCR条件同前所述
Domain C片段酶切体系如下：
胶回收步骤参照第一章7.1.4和7.1.5所述。
全长CPL基因表达蛋白载体pET28a的构建
pET28a载体用NdeI，NotI双酶切后，用Axygen胶回收试剂盒进行纯化
将pET28a载体和全长编码基因进行连接，连接体系如下：
反应条件：16℃连接过夜；
转化E.coli BL21菌株、PCR鉴定和测序参照1.2.3所述。
IPTG诱导新型重组蛋白表达
1) 挑取若干经鉴定阳性克隆子及空载体pET-28a的E.coli BL21转化克隆分别接种于含5ml LB培养基中(含Amp 100μg/ml)，32℃培养过夜；
2) 次日以1:50的接种量转接于LB培养基中(含Amp 100μg/ml)，200rpm/min培养至OD600为0.4～0.6之间；
3) 加入终浓度为0.3mmol的IPTG为诱导剂,37℃继续培养4h。
非变性条件下融合蛋白的 Ni-NTA agarose亲和纯化
1.5.1全长重组蛋白的大量诱导表达
1) 挑取经测序鉴定正确的E.coli BL21转化菌株接种于含50ml LB培养基中，37℃培养过夜；
2) 次日转接于2L的LB培养基中，200rpm/min培养至OD600为0.4～0.6之间，加入0.3mM的IPTG，30℃诱导培养4h；
3) 6000rpm 5min收集菌体，洗涤后用200ml裂解缓冲液（50mM Tris-HCl, 100mM NaCl, 1mM PMSF, pH8.0）悬浮，1500psi压力破壁；
4) 10000rpm离心收集沉淀，用Ni-NTA柱Binding Buffer重新溶解（20mM Tris，0.5M NaCl，20mM咪唑， PH8.0）；
5) 离心收集上清准备过柱纯化。
Ni-NTA亲和层析柱分离纯化全长重组蛋白
试剂配制
1) Binding Buffer：20mM Tris，0.5M NaCl， 20mM咪唑 PH8.0 ；
2) Elution Buffer：20mM Tris，0.5M NaCl， 500mM咪唑PH8.0 ；
3) MilliQ H2O ；
4) 20%乙醇：量取200ml 无水乙醇，配平至1000ml，上述溶液均用0.45μm滤膜抽滤，以防止柱子堵塞。
纯化方法
1) 用5柱体积的MilliQ H2O洗Ni-NTA agarose预装柱(5ml)至基线平稳，流速5ml/min；
2) 用10个柱体积Binding Buffer预平衡柱子，至基线再次平稳；
3) 将步骤1所得发酵液上柱，流速3ml/min ；
4) 上样结束后用Binding Buffer进行杂蛋白冲洗，流速5ml/min，直至流出液离子强度及UV达到基线位置（即上样前平衡液强度）；
5) 用Elution Buffer洗脱目的蛋白，根据紫外280吸收峰强度收集洗下来的目的蛋白；
6) 用10倍体积的MilliQ H2O洗柱；
7) 用5倍体积的20%乙醇洗柱，4℃保存。
重组蛋白除盐
1) 准备好MilliQ H2O，20%乙醇，用0.45um微孔滤膜过滤 ；
2) 用10柱体积的MilliQ H2O洗Desalting预装柱(5ml)至基线平稳；
3) 将纯化并超滤浓缩好的蛋白上样0.5ml；
4) 用10柱体积的MilliQ H2O洗脱，按OD280峰收集。
凝血酶切除His-tag：
使用凝血酶试剂盒对已经纯化好的重组蛋白进行酶切，按试剂盒要求按照下表加样：
| 10×凝血酶酶切Buffer | 100μl |
| 凝血酶（1U/μl） | 1μl |
| 重组蛋白（2mg/ml） | 500μl |
| MilliQ H2O | 400μl |
酶切条件：21℃ 16h
次日收集酶切完毕的重组蛋白用10KD超滤管超滤去除小分子量的标签，再经去内毒素试剂盒去除内毒素后用于细胞实验。
重组蛋白的混合淋巴细胞反应以及ConA转化实验
1.7.1 1小鼠淋巴细胞分离
1) 分别取BALB/c和C57小鼠各一只，断颈处死后浸泡于75%乙醇中消毒后无菌操作取出脾脏；
2) 加入5ml EZ-Seq Mouse淋巴细胞分离液研磨，转移到离心管中加入500ul 1640培养基；
3) 800g离心后吸出淋巴细胞层，再加入10ml的1640培养基颠倒洗涤；
4) 250g离心收集细胞并计数；
5) 用1640培养基调整细胞浓度为1×106，接入96孔培养板中，每孔100ul 。
双向混合淋巴细胞反应
1) 按下表分组，每孔总体积200μl。每组3个复孔
| 组别 | 加样 |
| 阳性刺激组 | B＋C |
| 阴性对照组 | C＋C 或B+B |
| 低剂量实验组 | B+C+2ng/μl 重组蛋白 |
| 高剂量实验组 | B+C+-10ng/μl 重组蛋白 |
注:B代表BALB/c小鼠淋巴细胞，C代表C57小鼠淋巴细胞
2) 37度，5％CO2培养箱内培养72h；
3) 每孔加入10ul的CCK8，37℃，5％CO2培养箱继续培养4h；
4) 取出，用M5酶标仪测量OD450；
5) 计算刺激指数SI：（阳性刺激组—实验组）/ 阳性刺激组。
转化实验
方法可参考双向混合淋巴细胞反应，按下表分组：
| 组别 | 加样 |
| 阴性对照组 | B |
| ConA刺激组 | B+5 ng/μl ConA |
| 低剂量实验组 | B + 5 ng/μl ConA + 2ng/μl重组蛋白 |
| 高剂量实验组 | B + 5 ng/μl ConA + 10ng/μl重组蛋白 |
1.7.4数据处理：
刺激指数SI＝反应组CPM 均值/阴性对照组CPM均值。
抑制率（Inhibited rate）＝（1－实验组SI/ ConA刺激组SI）×100％ 。
结果图5和图6显示重组的CPL蛋白在作用浓度2 ng/μl和10 ng/μl时，对双向混合淋巴细胞活化的抑制率分别为45％±2.4和71%±5.0，对ConA转化实验的淋巴细胞活化抑制率分别为52±3.5%和71%±3.0%。
综上，本发明成功的制备了重组蛋白，该融合蛋白可竞争性抑制CD28与B7分子的结合，并通过CD279及其配体途径抑制淋巴细胞的活化，实验显示该融合蛋白具有明显的免疫抑制作用，具有良好的应用前景。
<110> 复旦大学
<120> 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用
<130> AAA
<160> 10
<170> PatentIn version 3.3
<210> 1
<211> 1053
<212> DNA
<213>
<400> 1
atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60
atgttattca cagtgacagt ccctaaggaa ctgtacataa tagagcatgg cagcaatgtg 120
accctggaat gcaactttga cactggaagt catgtgaacc ttggagcaat aacagccagt 180
ttgcaaaagg tggaaaatga tacatcccca caccgtgaaa gagccacttt gctggaggag 240
cagctgcccc tagggaaggc ctcgttccac atacctcaag tccaagtgag ggacgaagga 300
cagtaccaat gcataatcat ctatggggtc gcctgggact acaagtacct gactctgaaa 360
gtcaaagctt cctacaggaa aataaacact cacatcctaa aggttccaga aacagatgag 420
gtagagctca cctgccaggc tacaggttat cctctggcag aagtatcctg gccaaacgtc 480
agcgttcctg ccaacaccag ccactccagg acccctgaag gcctctacca ggtcaccagt 540
gttctgcgcc taaagccacc ccctggcaga aacttcagct gtgtgttctg gaatactcac 600
gtgagggaac ttactttggc cagcattgac cttcaaagtc agatggaacc caggacccat 660
ccaactggcg gtggatccat gcatgttgct caaccagctg ttgttttggc ttcttctaga 720
ggtattgctt cttttgtttg tgaatacgct tctccaggta aggctactga agttagagtt 780
actgttttga gacaagctga ttctcaagtt actgaagttt gtgctgctac ttacatgatg 840
ggtaacgaat tgactttttt ggatgattct atttgtactg gtacttcttc tggtaaccaa 900
gttaacttga ctattcaagg tttgagagct atggatactg gtttgtacat ttgtaaggtt 960
gaattgatgt acccaccacc atactacttg ggtattggta acggtgctca aatttacgtt 1020
attgatccag aaccatgtcc agattctgat taa 1053
<210> 2
<211> 350
<212> PRT
<213>
<400> 2
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro
1 5 10 15
Arg Gly Ser His Met Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr
20 25 30
Ile Ile Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr
35 40 45
Gly Ser His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val
50 55 60
Glu Asn Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu
65 70 75 80
Gln Leu Pro Leu Gly Lys Ala Ser Phe His Ile Pro Gln Val Gln Val
85 90 95
Arg Asp Glu Gly Gln Tyr Gln Cys Ile Ile Ile Tyr Gly Val Ala Trp
100 105 110
Asp Tyr Lys Tyr Leu Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile
115 120 125
Asn Thr His Ile Leu Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr
130 135 140
Cys Gln Ala Thr Gly Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val
145 150 155 160
Ser Val Pro Ala Asn Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr
165 170 175
Gln Val Thr Ser Val Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe
180 185 190
Ser Cys Val Phe Trp Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser
195 200 205
Ile Asp Leu Gln Ser Gln Met Glu Pro Arg Thr His Pro Thr Gly Gly
210 215 220
Gly Ser Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg
225 230 235 240
Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr
245 250 255
Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu
260 265 270
Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp
275 280 285
Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr
290 295 300
Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val
305 310 315 320
Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Ala
325 330 335
Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp
340 345 350
<210> 3
<211> 32
<212> DNA
<213>
<400> 3
tctctcgaga aaagattatt cacagtgaca gt 32
<210> 4
<211> 26
<212> DNA
<213>
<400> 4
taaggtctca ctttgacttt cagagt 26
<210> 5
<211> 33
<212> DNA
<213>
<400> 5
tatggtctca aaagcttcct acaggaaaat aaa 33
<210> 6
<211> 76
<212> DNA
<213>
<400> 6
atagcggccg cttaatgatg atgatgatga tgagttggat gggtcctggg ttccatctga 60
ctttgaaggt caatgc 76
<210> 7
<211> 25
<212> DNA
<213>
<400> 7
agccatatgt tattcacagt gacag 25
<210> 8
<211> 35
<212> DNA
<213>
<400> 8
ataggatcca ccgccagttg gatgggtcct gggtt 35
<210> 9
<211> 26
<212> DNA
<213>
<400> 9
ataggatcca tgcatgttgc tcaacc 26
<210> 10
<211> 28
<212> DNA
<213>
<400> 10
atagcggccg cttaatcaga atctggac 28
Claims (8)
1.一种基因，称为CPL基因，其特征在于核苷酸序列为SEQ ID NO: 1所示。
2.一种基因工程重组表达载体，其特征在于：该重组表达载体包含权利要求1所述的基因。
3.一种基因工程表达蛋白质，称为CPL蛋白或CPL分子，其特征在于：由权利要求1所述基因编码，其氨基酸序列如SEQ ID NO: 2 所示。
4.一种基因工程重组的可表达CPL蛋白质的原核或真核细胞，即重组菌，其特征在于包含所述的重组基因及其相关的载体。
5.一种如权利要求3所述蛋白质的制备方法，其特征在于具体步骤如下：
I.取权利要求4所述的重组菌，以1:10~1:100的接种量转接于LB培养基中，200rpm/min培养至OD600为0.2～1.0之间；
II．加入终浓度为0.1~1.0mmol的IPTG为诱导剂，温度为30~40℃，诱导培养2~24h；
III．收集菌体，破壁，根据分子量、PI和亲和特性分离纯化并得到目的蛋白。
6.根据权利要求5所述的方法，其特征在于：所述重组菌以1:25-1：50的接种量转接于LB培养基中，培养至OD600为0.4～0.6之间；加入的诱导剂的终浓度为：0.2~0.5mmol，诱导温度30~40℃，诱导时间2~6h。
7.如权利要求4所述的蛋白质在制备免疫抑制剂中的应用。
8.一种免疫抑制剂，其特征在于：有效成分为权利要求3所述的蛋白质。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410107482.0A CN103923934B (zh) | 2014-03-22 | 2014-03-22 | 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410107482.0A CN103923934B (zh) | 2014-03-22 | 2014-03-22 | 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103923934A true CN103923934A (zh) | 2014-07-16 |
| CN103923934B CN103923934B (zh) | 2016-11-02 |
Family
ID=51142332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410107482.0A Expired - Fee Related CN103923934B (zh) | 2014-03-22 | 2014-03-22 | 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103923934B (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268563A (zh) * | 2000-04-18 | 2000-10-04 | 复旦大学 | 中国人共刺激信号抑制因子的基因工程制备方法 |
| CN1840191A (zh) * | 2003-02-14 | 2006-10-04 | 马菁 | 免疫调节剂及其应用 |
| WO2009029342A2 (en) * | 2007-07-13 | 2009-03-05 | The Johns Hopkins University | B7-dc variants |
| WO2011000426A1 (en) * | 2009-07-02 | 2011-01-06 | Nokia Corporation | Method, apparatus, system, and related computer program product for relay-sensitive routing |
| CN102199216A (zh) * | 2000-04-28 | 2011-09-28 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
| CN102227447A (zh) * | 2008-10-02 | 2011-10-26 | 新兴产品开发西雅图有限公司 | Cd86拮抗物多靶点结合蛋白 |
| CN102618565A (zh) * | 2011-03-01 | 2012-08-01 | 四川大学华西医院 | 一种ctla4融合蛋白及其制备方法和用途 |
| CN103172750A (zh) * | 2007-11-01 | 2013-06-26 | 珀西德治疗有限责任公司 | 免疫抑制性多肽与核酸 |
| WO2013192504A1 (en) * | 2012-06-22 | 2013-12-27 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
-
2014
- 2014-03-22 CN CN201410107482.0A patent/CN103923934B/zh not_active Expired - Fee Related
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268563A (zh) * | 2000-04-18 | 2000-10-04 | 复旦大学 | 中国人共刺激信号抑制因子的基因工程制备方法 |
| CN102199216A (zh) * | 2000-04-28 | 2011-09-28 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
| CN1840191A (zh) * | 2003-02-14 | 2006-10-04 | 马菁 | 免疫调节剂及其应用 |
| WO2009029342A2 (en) * | 2007-07-13 | 2009-03-05 | The Johns Hopkins University | B7-dc variants |
| CN103172750A (zh) * | 2007-11-01 | 2013-06-26 | 珀西德治疗有限责任公司 | 免疫抑制性多肽与核酸 |
| CN102227447A (zh) * | 2008-10-02 | 2011-10-26 | 新兴产品开发西雅图有限公司 | Cd86拮抗物多靶点结合蛋白 |
| WO2011000426A1 (en) * | 2009-07-02 | 2011-01-06 | Nokia Corporation | Method, apparatus, system, and related computer program product for relay-sensitive routing |
| CN102618565A (zh) * | 2011-03-01 | 2012-08-01 | 四川大学华西医院 | 一种ctla4融合蛋白及其制备方法和用途 |
| WO2013192504A1 (en) * | 2012-06-22 | 2013-12-27 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
Non-Patent Citations (3)
| Title |
|---|
| ADRIOUCH S等: "Improved immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.", 《FRONT MICROBIOL》, 29 September 2011 (2011-09-29) * |
| FIFE BT等: "Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.", 《IMMUNOL REV》, 31 August 2008 (2008-08-31) * |
| 夏国伟等: "生物免疫抑制治疗", 《复旦学报》, vol. 28, no. 4, 31 December 2001 (2001-12-31), pages 366 - 368 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103923934B (zh) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eisenberg et al. | Analysis of membrane and surface protein sequences with the hydrophobic moment plot | |
| Rojiani et al. | In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin. alpha. subunits | |
| Lemke et al. | Isolation and analysis of the gene encoding peripheral myelin protein zero | |
| Cox et al. | Alternative primary structures in the transmembrane domain of the chicken erythroid anion transporter | |
| TW321651B (zh) | ||
| CN101556287A (zh) | 一种新型蛋白质分子量标准及其制备方法 | |
| CN111217903B (zh) | 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用 | |
| CN108794619A (zh) | 一种高亲和pd-1蛋白突变体 | |
| CN103131676A (zh) | 表达重组人肿瘤坏死因子受体-Fc融合蛋白基因的家蚕重组杆状病毒及其制备方法和应用 | |
| CN102671185A (zh) | 少棘蜈蚣多肽毒素omega-SLPTX-Ssm1a的应用 | |
| CN111793134A (zh) | 一种用于癌症治疗中的药物、肿瘤疫苗及抑制剂 | |
| CN111234019B (zh) | 抗ctla-4纳米抗体、药物组合物及其应用 | |
| CN103923934A (zh) | 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 | |
| CN101280001A (zh) | 人SDF-1α的制备及由此获得的人SDF-1α及其用途 | |
| JPH02152990A (ja) | 細胞接着活性ポリペプチド | |
| Pourmand et al. | The Zn2+ binding domain of the human Ro 52 kDa protein is a target for conformation-dependent autoantibodies | |
| CN1936001A (zh) | 鹅B淋巴细胞刺激因子cDNA及其克隆方法和重组应用 | |
| JP3104178B2 (ja) | 機能性ポリペプチド | |
| CN104211808B (zh) | 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白的制备方法 | |
| Lunsford et al. | DNA-binding activities in Streptococcus gordonii: identification of a receptor-nickase and a histonelike protein | |
| CN116715749B (zh) | 一种与胶原具有特异结合能力vegf活性抑制蛋白及其制备方法与应用 | |
| CN102718846B (zh) | 活性增强的sec2突变蛋白及编码基因与制备和应用 | |
| CN101268100A (zh) | 对I类MHC亲和力提高的修饰的白细胞Ig样受体家族（LIR'S）及其在调节T细胞活性中的用途 | |
| EP3242681B1 (en) | Novel compounds for the treatment of cancer | |
| CN111153998B (zh) | 抗ctla-4纳米抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161102 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |